A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00096837

Enrollment

Registered

2004-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2006-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma

Brief summary

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Interventions

DRUGMotexafin Gadolinium Injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Relapsed or Refractory Multiple Myeloma * ≥ 18 years old * Able to provide consent for participation * ECOG status 0-2 Lab values: * ANC ≥ 1,000/µL * WBC count ≥ 2.0/µL * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 50,000/µL * AST and ALT ≤ 2 x ULN * Total Bilirubin ≤ 2 x ULN * Creatinine ≤ 2.0 mg/dL and * Not pregnant or lactating

Design outcomes

Primary

Measure	Time frame
Rate of complete response, partial response and stable disease (clinical benefit rate)	—

Secondary

Measure	Time frame
Progression-free survival	—
Safety and tolerability	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026